Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, Tennessee, United States.
Mol Pharm. 2011 Oct 3;8(5):1458-70. doi: 10.1021/mp200135e. Epub 2011 Jul 7.
The use of adult stem cells for therapeutic purposes has met with great success in recent years. Among several types of adult stem cells, mesenchymal stem cells (MSCs) derived from bone marrow (BM) and other sources have gained popularity for basic research and clinical applications because of their therapeutic potential in treating a variety of diseases. Because of their tissue regeneration potential and immune modulation effect, MSCs were recently used as cell-based therapy to promote revascularization, increase pancreatic β-cell proliferation, and avoid allograft rejection in islet transplantation. Taking advantage of the recent progress in gene therapy, genetically modified MSCs can further enhance and expand the therapeutic benefit of primary MSCs while retaining their stem-cell-like properties. This review aims to gain a thorough understanding of the current obstacles to successful islet transplantation and discusses the potential role of primary MSCs before or after genetic modification in islet transplantation.
近年来，成体干细胞在治疗方面的应用取得了巨大成功。在几种成体干细胞中，骨髓（BM）和其他来源的间充质干细胞（MSCs）因其在治疗多种疾病方面的治疗潜力，在基础研究和临床应用中受到了广泛关注。由于其组织再生潜力和免疫调节作用，MSCs 最近被用作基于细胞的疗法，以促进血管生成、增加胰岛 β 细胞增殖，并避免胰岛移植中的同种异体排斥反应。利用基因治疗的最新进展，经过基因修饰的 MSCs 可以在保留其干细胞特性的同时，进一步增强和扩大原代 MSCs 的治疗益处。本综述旨在深入了解胰岛移植成功的当前障碍，并讨论在基因修饰前后，原代 MSCs 在胰岛移植中的潜在作用。
